Your browser is no longer supported. Please, upgrade your browser.
Settings
SURF Surface Oncology, Inc. daily Stock Chart
SURF [NASD]
Surface Oncology, Inc.
Index- P/E- EPS (ttm)-1.09 Insider Own0.30% Shs Outstand27.98M Perf Week15.16%
Market Cap167.40M Forward P/E- EPS next Y-1.98 Insider Trans-83.38% Shs Float27.65M Perf Month5.82%
Income-28.00M PEG- EPS next Q-0.48 Inst Own86.10% Short Float1.55% Perf Quarter119.78%
Sales39.50M P/S4.24 EPS this Y-495.10% Inst Trans43.06% Short Ratio0.18 Perf Half Y96.72%
Book/sh2.92 P/B2.05 EPS next Y-130.20% ROA-20.10% Target Price10.33 Perf Year183.02%
Cash/sh3.23 P/C1.86 EPS next 5Y- ROE-38.40% 52W Range1.15 - 7.66 Perf YTD219.15%
Dividend- P/FCF- EPS past 5Y- ROI-88.70% 52W High-21.67% Beta-
Dividend %- Quick Ratio7.00 Sales past 5Y- Gross Margin- 52W Low421.74% ATR0.59
Employees49 Current Ratio7.00 Sales Q/Q168.10% Oper. Margin-71.20% RSI (14)59.12 Volatility11.47% 10.17%
OptionableNo Debt/Eq0.06 EPS Q/Q583.80% Profit Margin-70.90% Rel Volume0.29 Prev Close5.91
ShortableYes LT Debt/Eq0.06 EarningsMay 12 BMO Payout- Avg Volume2.35M Price6.00
Recom1.70 SMA209.86% SMA5013.37% SMA20092.06% Volume686,181 Change1.52%
Sep-19-18Initiated Robert W. Baird Outperform
May-14-18Initiated Goldman Neutral $17
May-14-18Initiated Evercore ISI Outperform $26
Aug-05-20 11:59AM  
Jun-12-20 09:45AM  
Jun-10-20 08:12PM  
May-28-20 04:10PM  
May-20-20 11:28AM  
07:15AM  
07:05AM  
May-15-20 11:46AM  
07:30AM  
May-14-20 07:30AM  
May-13-20 08:00AM  
May-12-20 06:20AM  
May-07-20 12:30PM  
Apr-23-20 08:00AM  
Mar-17-20 08:00AM  
Mar-12-20 10:39AM  
Mar-10-20 06:20AM  
Mar-06-20 11:30AM  
Feb-25-20 04:05PM  
Feb-19-20 11:30AM  
Feb-04-20 06:58AM  
Jan-28-20 07:12AM  
Jan-27-20 04:05PM  
Dec-23-19 10:24AM  
Dec-09-19 05:45PM  
Nov-26-19 11:07AM  
08:00AM  
Nov-25-19 08:00AM  
Nov-18-19 06:30AM  
Nov-12-19 07:45AM  
06:30AM  
Nov-07-19 08:00AM  
Oct-26-19 06:25PM  
Oct-07-19 07:00AM  
Sep-23-19 12:50PM  
Sep-18-19 05:55PM  
Sep-17-19 05:25PM  
Sep-03-19 04:05PM  
01:45PM  
07:00AM  
Aug-28-19 10:45AM  
Aug-27-19 08:00AM  
Aug-21-19 08:45PM  
Aug-20-19 01:15PM  
Aug-15-19 11:20PM  
Aug-14-19 08:55PM  
Aug-12-19 06:20PM  
Aug-08-19 09:05PM  
Aug-07-19 10:30PM  
09:30PM  
10:07AM  
09:05AM  
06:05AM  
Aug-06-19 05:52PM  
12:55PM  
10:30AM  
Aug-03-19 11:05AM  
Aug-01-19 01:15PM  
Jul-30-19 09:25PM  
Jul-29-19 01:15PM  
Jul-26-19 11:40PM  
Jul-25-19 03:09PM  
Jun-07-19 12:00PM  
May-31-19 01:33PM  
May-24-19 06:00AM  
May-15-19 04:00PM  
May-09-19 10:55AM  
07:00AM  
Apr-24-19 07:00AM  
Apr-01-19 07:00AM  
Mar-04-19 07:00AM  
Feb-21-19 09:01AM  
Feb-04-19 04:21PM  
Jan-16-19 04:50PM  
Jan-10-19 06:00AM  
Jan-04-19 07:00AM  
Dec-21-18 07:00AM  
Dec-18-18 04:01PM  
Dec-17-18 07:00AM  
Nov-20-18 07:00AM  
Nov-13-18 06:30AM  
Sep-19-18 03:43PM  
Aug-30-18 09:59AM  
Aug-14-18 07:00AM  
Jul-30-18 02:24PM  
Jul-03-18 06:23AM  
Jun-21-18 07:00AM  
Jun-20-18 10:01PM  
08:00AM  
Jun-18-18 03:31PM  
Jun-12-18 07:00AM  
Jun-11-18 05:07PM  
Jun-08-18 07:10AM  
Jun-07-18 04:42PM  
May-29-18 05:00PM  
May-21-18 07:25AM  
May-15-18 04:01PM  
Apr-23-18 04:30PM  
Apr-18-18 09:00PM  
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; SRF388 targeting interleukin 27; and SRF813 targeting CD112R. It also develops various earlier stage programs that targets other critical components of the tumor microenvironment, including regulatory T cells and natural killer cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies; and the Merck Sharp & Dohme Corp. to evaluate the safety and efficacy of combining Surface's SRF617, an investigational antibody therapy targeting CD39, with Merck's KEYTRUDA (pembrolizumab), the first anti-PD-1 therapy approved in the United States. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
New Enterprise Associates 14, 10% OwnerMay 20Sale3.66420,0001,535,5622,892,877May 22 04:56 PM
Goater JeffChief Executive OfficerFeb 05Buy3.235,00016,150262,000Feb 07 04:05 PM